The global cell therapy market size was estimated at USD 6.88 billion in 2025 and is anticipated to grow from USD 8.29 billion in 2026 to USD 38.24 billion in 2034, growing at a CAGR of 21.05% from 2026-2034. The global market is experiencing a well-determined growth due to various factors, such as rapid advancements in regenerative medicine, increasing prevalence of chronic and rare diseases, and rising adoption of advanced therapeutic solutions.
Download a Free Sample To learn more about this report,
The increasing focus on allogeneic and autologous therapies, technological innovations in cell manufacturing and delivery, supportive regulatory frameworks, and strategic collaborations among biotechnology, pharmaceutical companies, and contract development and manufacturing organizations (CDMOs), further drive the cell therapy industry growth.
Moreover, the expansion of cell therapy applications across oncology, cardiovascular, musculoskeletal, and other therapeutic areas is accelerating market adoption worldwide. Furthermore, initiatives by government agencies and non-profit organizations to improve access to innovative therapies, combined with the integration of advanced manufacturing technologies such as automation and 3D bioprinting, are further driving market growth. The growing investment in R&D, partnerships, and clinical trials for next-generation cell therapies is also strengthening the market’s long-term potential, positioning it as a transformative segment within the global healthcare industry.
Cell therapy is moving from conventional methods, which rely on standard cell culture and transplantation, to advanced 3D bioprinting approaches that enable the fabrication of complex, patient-specific tissue structures.
This shift highlights a move toward more personalized and effective cell-based therapies, which further enhances the market growth.
The cell therapy landscape in Asia is evolving with the growing development and adoption of mesenchymal stem cell (MSC) therapies.
Such a factor reflects a broader trend of integrating advanced stem cell therapies into clinical practice across the region, expanding treatment options for patients with previously limited alternatives.
The growth of autologous cell therapies is supported by the expansion of manufacturing capabilities, which presents as a significant driver for market growth.
Such facility enhances production capacity, improves supply reliability, and facilitates wider access to autologous therapies.
Cell therapies are highly expensive, often costing hundreds of thousands of dollars per patient, which creates major reimbursement and access challenges. To address this, outcomes-based payment models are being adopted, where reimbursement is directly tied to the therapy’s effectiveness in improving patient health.
This approach encourages the broader adoption of innovative cell therapies, which further enhances the market growth.
High cost and manufacturing complexity of advanced therapies, hinders the market growth as it limits the patient access.
Such factor highlights the ongoing affordability and reimbursement challenges, which further restrains the market growth.
Expansion of allogeneic CAR-T platforms, presents as a significant market opportunity as it offers scalable, off-the-shelf treatments.
Such factor acts as a significant step in expanding the scope of cell therapy applications beyond oncology into immune-mediated disorders.
Request Customizationto receive a tailored report.
The allogeneic cell therapy segment is anticipated to grow at a CAGR of 22.65 % from 2026 TO 2034. The growth is attributed to its scalability, off-the-shelf availability, and the ability to treat multiple patients from a single donor batch, which reduces production time and cost.
The oncology segment dominates the market with a revenue share of 38.17% in 2025. This growth is attributed to the strong pipelines as well as extensive clinical trials in oncology, which continue to attract the highest investments and collaborations globally.
The Biopharmaceutical and biotechnology companies segment dominated the market in 2025. This growth is attributed to their active collaborations with academic institutions and healthcare providers, the presence of supportive regulatory frameworks that enable faster product approvals, and the rising demand for personalized therapies.
Speak to an Analystto discuss market opportunities.
The North America region dominated the market with a revenue share of 57.35 % in 2025. The growth is attributed to factors such as strong presence of leading biotech and pharmaceutical companies, rapid adoption of CAR-T and stem cell therapies, supportive regulatory pathways from the U.S. FDA, significant R&D investments, and extensive clinical trial activity supported by advanced healthcare infrastructure and academic-industry collaborations.
The Asia Pacific region is the fastest-growing region with a CAGR of 23.76 % during the forecast timeframe. The growth is attributed to factors such as a larger patient population, increasing government initiatives to strengthen biotechnology infrastructure, rising investment in advanced therapies by regional manufacturers, and rapid expansion of GMP-certified cell facilities.
The cell therapy industry in U.S. is widely driven by improved patient access, supported by regulatory as well as payer progress. For example, in July 2025, as per the U.S. Centers for Medicare & Medicaid Services, 84% of Medicaid beneficiaries with sickle cell disease are in states participating in CMS’s Cell therapy (CGT) Access Model.
The market in the UK is propelling due to the rapid expansion of GMP manufacturing capacity, NHS adoption of CAR-T therapies and new regulations to enhance the manufacturing of cell therapies. For example, in July 2025, as per the Association for the Advancement of Blood and Biotherapies, the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) introduced “The Human Medicines (Amendment) (Modular Manufacture and Point of Care) Regulations 2025” for the on-site manufacture of advanced therapies, including cell therapies.
In Germany, the market is driven by the strong industry and government initiatives. For example, in June 2024, as per DZIF, the government launched the National Strategy for Gene and Cell-Based Therapies to provide regulatory guidance and improve patient access nationwide.
The cell therapy market in China is fuelled by the strong manufacturing investments as well as regulatory reforms and focus of companies towards the development of advanced therapies. For example, in June 2025, CARsgen Therapeutics Holdings Limited announces that the National Medical Products Administration (NMPA) of China has accepted the New Drug Application (NDA) for satricabtagene autoleucel, an autologous CAR-T cell product for the treatment of Claudin18.2 in patients who have failed at least two prior lines of therapy.
India continues to position itself in the cell therapy market, due to the rise of affordable home-grown CAR-T treatments. For example, in April 2024, as per the PIB, India launched its first homegrown genetic therapy, NexCAR19, developed via the collaborations between IIT Bombay, Tata Memorial Centre, and ImmunoACT.
Unlock Regional Insightsto access country-level data, & regional trends.
The global cell therapy market is highly fragmented in nature due to presence of numerous biotechnology startups, academic spin-offs, and mid-sized companies alongside a few major pharmaceutical players such as Novartis AG, Gilead Sciences, Inc and Bristol-Myers Squibb Company, Bluebird Bio, Inc., and Others.
The industry participants are inclined towards adopting key business strategies, such as strategic collaborations, product approvals, acquisitions, and product launches, to gain a strong foothold in the cell therapy market.
Phoenix SENOLYTIX is a company that uses advanced technologies to develop novel gene therapies.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanashri Bhapakar is a Senior Research Associate with 3+ years of experience in the Biotechnology sector. She focuses on tracking innovation trends, R&D breakthroughs, and market opportunities within biopharmaceuticals and life sciences. Dhanashri’s deep industry knowledge enables her to provide precise, data-backed insights that help companies innovate and compete effectively in global biotech markets.
We are featured on:
sales@straitsresearch.com